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Evan Ingley*Abstract: Src family kinases such as Lyn are important signaling intermediaries, relaying and modulating different
inputs to regulate various outputs, such as proliferation, differentiation, apoptosis, migration and metabolism.
Intriguingly, Lyn can mediate both positive and negative signaling processes within the same or different cellular
contexts. This duality is exemplified by the B-cell defect in Lyn−/− mice in which Lyn is essential for negative
regulation of the B-cell receptor; conversely, B-cells expressing a dominant active mutant of Lyn (Lynup/up) have
elevated activities of positive regulators of the B-cell receptor due to this hyperactive kinase. Lyn has well-
established functions in most haematopoietic cells, viz. progenitors via influencing c-kit signaling, through to
mature cell receptor/integrin signaling, e.g. erythrocytes, platelets, mast cells and macrophages. Consequently, there
is an important role for this kinase in regulating hematopoietic abnormalities. Lyn is an important regulator of
autoimmune diseases such as asthma and psoriasis, due to its profound ability to influence immune cell signaling.
Lyn has also been found to be important for maintaining the leukemic phenotype of many different liquid cancers
including acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and B-cell lymphocytic leukaemia
(BCLL). Lyn is also expressed in some solid tumors and here too it is establishing itself as a potential therapeutic
target for prostate, glioblastoma, colon and more aggressive subtypes of breast cancer.
Lay Abstract: To relay information, a cell uses enzymes that put molecular markers on specific proteins so they
interact with other proteins or move to specific parts of the cell to have particular functions. A protein called Lyn is
one of these enzymes that regulate information transfer within cells to modulate cell growth, survival and
movement. Depending on which type of cell and the source of the information input, Lyn can positively or
negatively regulate the information output. This ability of Lyn to be able to both turn on and turn off the relay of
information inside cells makes it difficult to fully understand its precise function in each specific circumstance. Lyn
has important functions for cells involved in blood development, including different while blood cells as well as red
blood cells, and in particular for the immune cells that produce antibodies (B-cells), as exemplified by the major
B-cell abnormalities that mice with mutations in the Lyn gene display. Certain types of leukaemia and lymphoma
appear to have too much Lyn activity that in part causes the characteristics of these diseases, suggesting it may be
a good target to develop new anti-leukaemia drugs. Furthermore, some specific types, and even specific subtypes,
of solid cancers, e.g. prostate, brain and breast cancer can also have abnormal regulation of Lyn. Consequently,
targeting this protein in these cancers could also prove to be beneficial.
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Lyn as a signaling intermediary
Both receptor and non-receptor protein tyrosine kinases
are essential enzymes in many cellular signaling pro-
cesses regulating cell growth, differentiation, apoptosis,
migration, immune responses, adhesion and metabolism
[1]. Members of the Src family of tyrosine kinases are
signaling intermediates that can control aspects of these
and other biological processes [2,3].
Lyn is a member of the Src family of intracellular
membrane-associated tyrosine kinases (SFK). Each
member has a unique N-terminal region (SH4) encoding
a myristoylation site, and may contain one (e.g. Lyn) or
two (e.g. Fyn) palmitoylation sites [4], followed by hom-
ologous domains for protein interaction (SH3 and SH2),
as well as a kinase (SH1) domain (Figure 1) [5]. Lyn has
two splice variants (via exon 2) that result in the gener-
ation of p53 and p56 kDa protein isoforms, designated
as LynA (p56) and LynB (p53), which differ by a 20
amino acid region in the SH4 domain that encompassesFigure 1 Regulation of Lyn and Lyn pathways. A) Domain
architecture of Lyn. Schematic of Lyn protein functional domains
and motifs, unique (UN), Src Homology 3 (SH3), Src Homology 2
(SH2), and Kinase domains, proline motif in the hinge region (P),
amino terminal lipid modifications are indicated; myristoylation
(navy blue) and palmitoylation (cyan). Important pY motifs that are
phosphorylated in the inactive (pY508, red) and active (pY397,
green) kinase are indicated, as is the LynA/p56 isoform-specific motif
pY32 that may modulate activity/interactions. Intramolecular
interactions between the SH3 domain and the hinge (P) region, as
well as the SH2 domain and the C-terminal pY508 motif are shown.
B) Lyn regulation of positive and negative signaling pathways. Lyn
regulates multiple signaling pathways by interacting with and/or
phosphorylating different molecules that can mediate both the
activation/enhancement as well as the inhibition/termination of
signaling networks, as illustrated.a pY motif (pY32) [6,7]. The reversible N-terminal lipid
modification (palmitoylation) and isoform specific pY32
motif potentially complicate understanding Lyn’s func-
tion through their latent ability to regulate activity, inter-
actions, and subcellular localization. As with other Src
family kinases Lyn is regulated by protein interactions
through its SH2/SH3 domains as well as via phosphoryl-
ation status (Figure 1A) [8]. In its inactive state Lyn is
phosphorylated at its carboxyl terminus by C-terminal
Src kinase (Csk) creating a binding site for its own SH2
domain. Lyn’s SH3 domain can bind an intramolecular
proline-motif situated between the SH2 and kinase
domains (hinge region), helping generate a stabilized in-
active kinase confirmation. Activation of Lyn involves
dephosphorylation of the C-terminal tyrosine (Y508) by
phosphatases such as CD45 [9] and SHP-2 [10], as well
as through interactions with SH2 and/or SH3 domain
binding motifs, which compete with Lyn's own SH3/SH2
intramolecular interaction sites, thus releasing the auto-
inhibitory configuration of the kinase domain. Lyn can
then trans-autophosphorylate within the activation loop
(Y397) to generate a highly active enzyme. Phosphoryl-
ation of this loop alters its structure such that the Mg-
ATP pocket becomes more accessible, thus increasing
kinase activity potential [11]. The structure of Lyn’s kin-
ase domain has been solved in an active but unpho-
sphorylated apo form as well as in complex with several
inhibitors, revealing the molecular basis for its inhibition
by these drugs [12]. In vitro analysis indicates that the
Y397 phosphorylation status potentiates the greatest ac-
tivity regulation [13,14], however, in vivo, this may be
substantially modulated by the C-terminal motif and/or
SH2/SH3 domain interactions. Indeed, the activation/in-
activation regulatory cycle of Lyn is further controlled
by its association with different scaffold/adaptors that
are restricted to different subcellular compartments,
such as Cbp/PAG1, which predominantly resides within
lipid rafts [15-18]. In the inactivation cycle of Lyn, phos-
phatases such as SHP-1 and SHP-2, which are them-
selves attracted to molecules phosphorylated by Lyn, are
known to dephosphorylate the pY397 activation loop
site, and are thus important in down-regulating this
emzyme [19].
The involvement of Src family kinases including Lyn
in various signaling cascades is gradually being eluci-
dated (reviewed in [3]). While Lyn was originally identi-
fied as a hematopoietic specific kinase it is expressed in
many tissues and is involved in the transmission of sig-
nals from a number of receptors such as B-cell receptor
[20,21], GM-CSF-receptor [22], FcER1 [23], Epo-
receptor [24-26], and c-kit [27], among others (reviewed
in [28,29]), as well as integrins [30]. Lyn phosphorylates
a number of signaling molecules, including the immu-
noreceptor tyrosine-based inhibitory/activation motifs
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as PI-3 kinase, FAK, ras-GAP, PLCγ1/2, HS1 [32], Cbp/
PAG1 [15,16], STAT5 [33] and MAP kinase. Lyn−/− mice
(Figure 2A) are viable but display defects in their im-
mune system [20], myeloid lineage [34], erythroid com-
partment [26,35], and have neuronal [36] and prostate
tissue deficiencies [37]. Mice expressing a constitutively
active Lyn (Lynup/up, Figure 2B) also develop abnormal-
ities of the myeloid and lymphoid systems [21,34], and
our preliminary work illustrates they have erythroid ab-
normalities (unpublished observations). Further investi-
gation is required to delineate any alterations to other
tissues/organs in these hyperactive Lyn expressing mice.
Intriguingly, Lynup/up mice do not appear more prone to
developing any neoplasia, while Lyn−/− animals have an
age-dependent accumulation of disseminated macro-
phage tumors [34]. While much emphasis is placed on
the kinase activity of Lyn, and indeed other SFK/tyrosine
kinases, as providing the paramount down-stream sig-
naling capacity of this enzyme, the recent identification
of major immune cell signaling differences in mice car-
rying kinase dead alleles of Lyn (LynMld4/Mld4, [38], WeeB
[39], Figure 2C, D) compared to those that have LynFigure 2 Mutations of Lyn in genetically engineered mice. A) Deletion
highlighting the generation of Lyn−/− mice through the replacement of exo
transcribed in the opposite orientation to the Lyn gene. B) Lynup/up mice co
phenylalanine (Y508F) that is unable to be phosphorylated. C) LynMld4/Mld4 m
activation look, to a lysine (T410K), which inhibits the activity of the enzym
glutamic acid is changed to a glycine (E260G), inhibiting binding of Mg-AT
PNT domain of Tel (ETV6) with a truncated Lyn lacking its regulatory UN/SH
Domains and motifs of Lyn are as described in Figure 1.deleted (Lyn−/−), implies there are important scaffolding
functions for this molecule in addition to its enzymatic
activity.
In addition to the normal function and crucial role of
Lyn in B-cell receptor signaling (reviewed in [31]), as
well as several growth/cytokine receptor signaling sys-
tems [29], it has also been noted to function in numer-
ous mature as well as progenitor blood cells. While Lyn
has important functions in Epo-receptor signaling in
erythroid progenitors [26,35,40], it is also the most
abundant SFK in mature erythrocytes [41] and phos-
phorylates important cell shape controllers/ion transpor-
ters in these cells e.g. Band 3, in response to physico/
chemical regulators of red cell function [42,43]. Lyn is
also involved in thrombopoietin(Tpo)-receptor signaling
in megakaryocytes [44], as well as in mature platelets
[45,46], where it functions in regulating integrin and
FcRγ signaling, crucial for their function in adhesion and
aggregation [47,48]. Lyn has important signaling func-
tions in mast cells; engagement of the FcERI activates
Lyn to regulate mast cell degranulation [49-51]. Again,
in this system as in others, Lyn appears to have both
positive and negative regulatory roles. A recent studyof exon 1 in Lyn−/− mice. Schematic of the genomic region of Lyn
n one and surrounding sequences with a PGK-Neo cassette,
ntain a point mutation of the C-terminal tyrosine, generating a
ice contain a point mutation of a threonine at the end of the
e. D) WeeB mice contain a point mutation in the glycine loop, a
P, resulting in an inactive enzyme. E) The Tel-Lyn fusion juxtaposes the
3/SH2 domains, generating a constitutively active kinase fusion.
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two molecular species of Lyn (LynA, p56 and LynB,
p53), within platelets, utilizing a background of Lyn−/−
cells within which the specific isoforms of Lyn were then
expressed either individually of in combination [52]. Not
only did LynA and LynB have differing signaling capaci-
ties, but they also displayed differential association with
effector molecules. Indeed to restore the wild-type sig-
naling, both LynA and LynB isoforms needed to be co-
expressed, either isoform alone producing abnormal
responses [52]. Extending these isoform specific studies
to the other cell systems that involve Lyn will be of great
interest, and may help delineate the molecular mechan-
isms behind the duplicitous nature of this enzyme.
It is clear that Lyn has important functions in numer-
ous hematopoietic cell types, from early stem/progeni-
tors (signaling via the stem cell factor receptor/c-kit
[27]) through to multiple lineages of the lymphoid sys-
tem (e.g. B-cell) and the myeloid system (e.g. macro-
phages, erythroid cells, platelets, mast cells, eosinophils).
Interestingly, while Lyn is not expressed in T-cells, it can
have a significant impact upon T-cell function through
modulating signaling in cells that interact with T-cells
[53]. Within these signaling pathways it is becoming ap-
parent that Lyn has a dual role by both activating and
inhibiting signaling pathways, thus it is aptly described
as a signaling modulator (Figure 1B). Within the non-
hematopoietic cells (e.g. prostate, colon, breast, neur-
onal/astrocytes) that express Lyn, its role in activating/
inhibiting various signals still requires further elucida-
tion, however, most studies so far point to it being a
positive regulator [36,37,54-56].
Immune diseases regulated by Lyn
Lyn has unique roles in B lymphocyte signaling
(reviewed in [31]), mediating positive and inhibitory sig-
nals, as highlighted through the B-cell phenotypes when
Lyn is deleted (Lyn−/−), inactivated (LynMld4/Mld4, WeeB),
and hyper-activated (Lynup/up) in the whole animal
[20,34,38,39]. At the signaling level there are the
expected major differences between Lyn−/− and Lynup/up
mice, i.e. reduced phosphorylation with Lyn-deficiency
and hyper-phosphorylation with constitutively active
Lyn. Dysregulation of Lyn results in antibody-mediated
autoimmune disease, leading to speculation that Lyn
may be a key component in such clinically similar dis-
eases, such as systemic lupus erythematosus (SLE).
While there is limited evidence of a direct involvement
of Lyn in SLE [57,58], the physiological similarities be-
tween dysregulated Lyn mice and autoimmune diseases
may make these animals useful models of such human
diseases. It is very interesting to note that mice with de-
fective Lyn kinase activity (LynMld4/Mld4, WeeB), but still
expressing Lyn protein have a less severe immunedysfunction phenotype than those with Lyn fully-ablated
[38,39]. It is also becoming apparent that immune dis-
eases that are thought to be mediated by cells that don’t
express Lyn, i.e. T-cells in asthma, can also be modu-
lated by dysregulation of Lyn [53]. Inhibiting Lyn kinase
activity could inhibit airway eosinophilia, as Lyn has im-
portant functions in IL-5 receptor signaling [59], in
which it is associated with asthma [60]. However, the
cellular changes of Lyn−/− mice would suggest they
would be more prone to asthma. Indeed, when Lyn-defi-
cient animals are challenged with an asthma-induction
model, they develop a persistent and more severe form
of the disease than control mice [53]. This effect may be
due to the lack of inhibitory Lyn-mediated signaling in
the many non-T-cell immune regulators and mediators,
i.e. B-cells, macrophages, eosinophils, neutrophils, den-
tritic cells and mast cells (reviewed in [22,23]), in these
Lyn−/− mice, resulting in an inability to negatively regu-
late Th2 immune responses. Further, the enhanced Th2
response in Lyn−/− mice also appears to be contributed
to by the lack of Lyn signals through the FcERI in baso-
phils [61]. With Lyn also being intimately involved in
FcERI signaling within mast cells, a potential to regulate
mast cell inflammation associated with allergic reactions
also exists (reviewed in [23]). Interestingly, while Lyn−/−
B cells can be autoreactive, the immune disease that they
cause is strongly linked to the IL-6-dependent inflamma-
tory environment that they induce [62]. Additionally,
hyperactive myeloid cells produce BAFF (B lymphocyte
stimulator) that activates B-cells, but also activates T-
cells to release IFNγ, creating an inflammatory loop that
exacerbates the autoimmunity of Lyn−/− animals [63].
There is some interesting data suggesting that the sub-
cellular localization of Lyn is crucial for its normal func-
tioning [64-66]. Lyn can be cleaved by caspase 3 and 7
within its N-terminal unique region, resulting in removal
of the myristoylation and single palmitoylation sites,
resulting in the cleaved form localizing exclusively to the
cytosolic compartment, while full-length Lyn can be
found predominately in the plasma membrane (often
within lipid rafts) as well as the cytosol [64,66]. The pro-
duction of this cleaved form of Lyn occurred in B-cells
in response to induction of apoptosis, such as via BCR
ligation [66] and functions as a suppressor of apoptosis
[64]. Intriguingly, when this cleaved form of Lyn is ubi-
quitously over-expressed in transgenic mice [65], STAT3
is activated and NFκB inhibited, and it induces a skin in-
flammatory syndrome, very similar to that seen in psor-
iasis. Indeed in skin biopsies of psoriasis sufferers the
cleaved form of Lyn could be detected. This phenotype
was dependent upon the presence of a TNFα/TNF-re-
ceptor axis, and was ameliorated in Rag1-deficient mice
highlighting the involvement of a T-cell response in the
observed pathogenesis. Consequently, not only is the
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tion, but also its sub-cellular localization.
Leukaemia/Lymphoma and Lyn
The level and/or activity of tyrosine kinases including
members of the Src family kinases (SFK) are often ele-
vated in human neoplastic cells and their activity can
correlate with disease severity/metastatic potential [67-
69]. Recent advances in the development of small mol-
ecule inhibitors of tyrosine kinases has resulted in great
success in treating particular neoplasms and the thera-
peutic advantages of these reagents is illustrated by the
enormous success of Imatinib mesylate (Gleevec,
STI571) and Dasatinib for the treatment of CML [70],
and the recent release of Tykerb (lapatinib ditosylate)
[71] and Sutent (Sunitinib) [72] for the treatment of
solid tumours such as breast, lung and renal cancer.
While in vivo manipulation of Lyn through knockout
(Lyn−/−), inactivation (LynMld4/Mld4, [38]), and hyper-
activation (Lynup/up) mouse models have not provided
strong evidence for this kinase having a primary role in
initiating neoplasia, substantial evidence does exist im-
plicating it in regulating cancer/leukaemia cell biology
[37,55,73-76]. These studies are suggestive that Lyn can
be utilized in an oncogene addiction role in these neo-
plastic cells, subsequent to transformation initiation
events involving other molecules. Further, it will be use-
ful to undertake crosses of Lyn−/− and Lynup/up mice
with other regulators of oncogensis to delineate pathway
interactions. A recent study found that combining a lack
of Lyn with a lack of phospholipase beta 3 (PLCβ3)
causes a chronic myelomonocytic leukaemia through
reduced SHP-1 activity resulting in enhanced STAT5
phosphorylation [77].
Evidence is mounting that strongly implicates an im-
portant role for Lyn in several types of leukaemia and
lymphoma, especially chronic myeloid leukaemia (CML)
[76], acute myeloid leukaemia (AML) [75,78], chronic
lymphocytic leukaemia (CLL) [79], B-cell acute lympho-
blastic leukaemia (B-ALL) [74], B-cell chronic lymphocytic
leukaemia (B-CLL) [79], and B-Non Hodgkin’s lymph-
omas (B-NHL) [80]. Recently, Lyn has also been identified
as a fusion in myelo-proliferative disorders [81].
An important role for Lyn in both chronic and acute
myeloid leukaemic cells has been suggested by several
studies [75,76,82-84]. In an analysis of primary AML
cells, 76% had elevated Lyn kinase activity, while none
had constitutive JAK2 activation; moreover, inhibition of
Lyn activity (using genetic and small molecule inhibi-
tors) in AML cell lines substantially decreased cell
growth [75]. Recent studies have also confirmed the
common activation of Lyn in primary AML, and its crit-
ical role in maintaining proliferation and anti-apoptotic
pathways in these cells [78]. Further, Lyn is a signalingcomponent of the Fms-like tyrosine kinase 3/internal
tandem duplication (FLT3/ITD)-specific pathway linking
FLT3/ITD to STAT5. FLT3/ITD is the most common
mutation in human adult AML and Lyn binds with high
affinity to this mutated receptor. Down-regulation of
Lyn/Src family kinases in these AML cells by siRNA or
small molecule inhibitors substantially ameliorated their
growth in vitro and tumor establishment and growth
in vivo, as well as phosphorylation of important down-
stream FLT3/IDT mediators such as STAT5 [85]. One of
the standard treatments for AML is through differenti-
ation induction by all-trans-retinoic acid (ATRA), and
recent data has shown a potentially important modula-
tion of this pathway by Lyn [86]. Here, Lyn inhibitors,
such as Dasatinib, enhanced the effectiveness of ATRA
through a positive feedback loop involving a scaffolding
protein (KSR1) that complexes regulators of the MAP
kinase pathway with Lyn, illustrating the potential for
using Lyn/SFK inhibitors as adjunct therapies in com-
bination with other anti-AML effectors [86].
A number of reports have illustrated that while the
BCR-Abl fusion protein is the initiating molecule for
CML, there is a crucial down-stream role for Lyn in BCR-
Abl induced leukemogenesis [82,83]. Not only does Lyn
bind BCR-Abl and is activated by it [84], but Lyn can also
phosphorylate BCR-Abl and modulate its ability to trans-
form cells [87]. There are other direct links between Lyn
and BCR-Abl signaling pathways as Lyn phosphorylates
the Y177 motif of BCR-Abl [88], resulting in recruitment
of the adaptor Gab2, a principle activator of the PI-3 kin-
ase pathway, both of which are essential for BCR-Abl
oncogenesis [89]. Lyn is also involved in other signaling
pathways in CML cells, including through BCR-Abl acti-
vation of JAK2 that then activates Lyn by preventing SHP-
1 from turning off Lyn activity [90]. Interestingly, when
the CML cell line K562 is selected for Imatinib resistance,
the resultant cell line (K562R) has elevated Lyn levels and
kinase activity, as apposed to BCR-Abl mutations; their
sensitivity to this drug is regained upon down-regulation
of Lyn [76]. Significantly, in primary CML cells from
patients that have acquired Imatinib resistance, elevated
Lyn levels also appear commensurate with the develop-
ment of this drug resistance [76]. A study of drug-
resistant blast crisis BCR-Abl (+) leukaemic cells showed
that Lyn is crucial for their survival. Ablation of Lyn from
these cells resulted in the induction of apoptosis, while
normal CD34+ stem cells were not affected by Lyn abla-
tion [91]. Detailed phosphoproteomic analysis of Bcr-Abl
transformed cells [92] has revealed significant cross talk
between Bcr-Abl and the negative feedback loops that
control Lyn signaling via Cbp/PAG1. The protein Cbp/
PAG1 [15,17,18] is a scaffold molecule involved in recruit-
ing both the inhibitory kinase Csk, which inturn also
recruits the inhibitory phosphatase PTPN18 [93], as well
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the enzymatic inactivation of Lyn (through Csk phosphor-
ylation of the C-terminal tyrosine of Lyn, and PTPN18
dephosphorylation of the activation loop motif) as well as
degradation of Lyn via the proteasome through its poly-
ubiquitination mediated by SOCS1. In these CML cells
the Bcr-Abl kinase overpowers the negative feedback
loops initiated by its activation of Lyn through activation
of the phosphatase Shp2 that is able to dephosphorylate
Cbp/PAG1 thus mitigating its ability to turn off the Lyn
signals [92]. It is also very interesting to note that the sec-
ond generation (T315I non-effective, e.g. Dasatinib [94]
and Bafetinib [95]) and third generation (T315I effective,
e.g. Ponatinib [96]) anti-CML drugs, predominantly devel-
oped to combat the different point mutations in BCR-Abl
that are the more common causes of Imatinib resistance,
are also potent and effective inhibitors of Lyn [12]. It will
be interesting to see if these inhibitors that have relatively
few side-effects are useful chemotherapeutic agents for
other leukaemias/lymphomas or even solid tumors that
are shown to utilize Lyn for maintaining their neoplastic
state, or in other diseases that appear to involve Lyn, e.g.
autoimmune diseases.
Interestingly, in B-Non Hodgkin’s lymphomas (B-
NHL) there appears to be a Lyn/Cbp/STAT3 signaling
complex, not present in ALK+ T lymphoma or Hodgkin-
derived lymphoma cells, that doesn’t contain the Lyn in-
activating Csk kinase and promotes survival signals in
these lymphomas. When this signaling complex was
inhibited or down-regulated, these lymphoma cells had
substantially reduced survival [80]. This study suggests
that neoplastic cells may hijack Lyn complex mediators,
i.e. Cbp/PAG1, that are normally involved in turning off
Lyn signals, and transforming them from these inhibi-
tory regulators [15-18] to positive signaling mediators.
B-cell chronic lymphocytic leukaemia (B-CLL) cells
contain anomalous Lyn levels, much higher than those
seen in normal B-cells (which are a major cell type for
natural Lyn expression). In B-CLL cells Lyn is present
throughout the cytoplasm and not just localized to the
plasma membrane as in normal B-cells. Further, they
have substantial basal Lyn kinase activity that is un-
responsive to IgM stimulation, unlike that seen in
non-malignant cells. Small molecule Lyn inhibitors were
effective at inducing apoptosis in these B-CLL cells sug-
gesting that Lyn contributes to negating the apoptosis
pathway in this form of leukaemia, and suggests altered
localization of Lyn can contribute to its involvement in
oncogensis [79]. Interestingly, in B-CLL cells overexpres-
sing the phosphatase PTPN22, their acquired inhibition
of antigen-induced apoptosis and positive regulation of
an anti-apoptotic Akt pathway, is due to a selective un-
coupling of the Akt pathway that Lyn regulates down-
stream of the B-cell receptor [97]. Here PTPN22dephosphorylates the activation loop of Lyn, turning off
its kinase activity, and consequently its pro-apoptotic
pathways down-stream of the B-cell receptor [97]. Taken
together, these studies suggest that its not just the level
of Lyn activity that is important but also its localization
and interaction with regulators that can influence wea-
ther or not it functions as a positive effector or negative
regulator in B-cells/B-cell leukaemia.
The potential for Lyn’s kinase activity to have a direct
capacity to promote a myeoproliferative/leukaemic pheno-
type was illustrated by studies screening a cDNA library
fused to Tel (ETV6), a common fusion partner in AML
[98]. Here Tel-Lyn was identified in nearly half of all the
transforming initiating independent fusion events. Subse-
quently, Tel-Lyn fusions (Figure 2E) have now been identi-
fied in primary myelofibrosis patients with blastic
transformation [99]. This fusion between Tel and the kin-
ase domain of Lyn directly activates STAT5, independent
of JAK2, to cause neoplastic transformation and myelofi-
brosis, which was substantially dependent upon STAT5, i.
e. removal of STAT5 essentially prevented the Tel-Lyn fu-
sion from inducing myelo-proliferation [81]. It is interest-
ingly to speculate that the patient with the Tel-Lyn fusion
could have benefited from treatment with second or third
generation CML drugs (e.g. Dasatinib), which are highly
potent Lyn kinase inhibitors, instead of the Immatinib
therapy they received prior to succumbing to their disease.
These studies show that Lyn, while rarely a primary
causative agent in leukaemia/lymphoma, is nonetheless
often intimately involved in the oncogenic signaling
cascades within these neoplastic cells. Further, that sev-
eral cases illustrate that altering Lyn complexes and
localization appear important for Lyn to play an import-
ant oncogenic role. While altering just its kinase activity
without altering its signaling complexes/localization may
have minimal oncogenic consequences. Consequently,
the development and use of anti-Lyn/anti-Lyn-pathway
therapies has potential usefulness in the treatment of
certain types of leukaemia/lymphoma.
Involvement of Lyn in solid tumors
Considerable evidence implicates tyrosine kinases in the
development of many types of solid cancer as well as
leukaemia via their involvement in numerous growth
factor signaling cascades (reviewed in [100]). Ever since
the discovery of the transforming capacity of the Src
family of kinases, indeed Src was the first identified
oncogene, causing sarcomas in chickens [101], substan-
tial effort has gone into determining if this family of
genes are mutated in human cancers. While only a few
instances have found them to be genetically altered in
solid cancer [102], their activity/levels, as illustrated re-
cently [103], are commonly altered. Lyn has also been
specifically implicated in solid cancers, namely prostate
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glioblastoma [56], and breast cancer [105]. Indeed, re-
cent proteomic analysis of 130 tumor lines showed that
Lyn, as well as Src and Lck are some of the most con-
sistently activated tyrosine kinases in many types of can-
cer cells [103].
Expression of Lyn has been detected in colorectal
tumours that are metastatic, but not at earlier stages of
cancer development or in normal tissue [106]. Colon
carcinoma cells utilize Lyn downstream of a variant form
of the cell surface CD44 molecule in the activation of
the Akt anti-apoptotic pathway, and drug-resistant cells
show elevated Lyn kinase activity [54]. Further, this
pathway also appears to regulate the directional migra-
tion of these cells [107]. Surprisingly, Lyn is expressed at
high levels in most prostate cancer cell lines and primary
prostate tissue [37,108], and Lyn−/− mice have signifi-
cantly smaller prostates with fewer proliferating cells
than wild-type animals [37]. Lyn also regulates signaling
mechanisms in prostate cancer cells that influence cell
migration [108], and primary prostate cancer tissues
have elevated Lyn levels. Significantly, inhibition of Lyn
in prostate cell lines using a peptide designed to act as a
competitive inhibitor of the substrate binding site of the
kinase domain, resulted in reduced proliferation not only
in vitro but also in mice carrying prostatic cancer xeno-
grafts [37]. The level of inhibition correlated with the
level of Lyn expression in these prostate cell lines, sup-
porting the proposed mechanism of action of this pep-
tide inhibitor [37]. Further, targeting Lyn using the small
molecule inhibitor Dasatinib substantially reduces lymph
node metastasis of prostatic cancer cells as well as the
growth of the primary xenografted tumor [109]. Intri-
guing data looking at the ability of different SFKs to ini-
tiate prostate epithelia transformation showed Src and to
a lesser extent Fyn, but not Lyn, have this capacity
when expressed in their hyper-active forms, partially
dependent upon their different N-terminal lipid modifi-
cations [110]. Potentially, these studies lend support to
the hypothesis that transformed cells may utilize Lyn in
the maintenance of their phenotype, making it a legitim-
ate therapeutic target, but that Lyn itself is not a primary
initiator of transformation.
In Ewing’s sarcoma, a poorly differentiated bone/soft
tissue cancer that is characterized as sharing a common
translocation generating an EWS-ETS fusion, Lyn also
appears as a potential therapeutic target [104]. Using
RNAi or small molecule inhibitors to down-regulate
Lyn, the growth and metastatic capacity of these Ewing’s
sarcoma lines was substantially inhibited both in vitro
and in vivo. It also appeared that the EWS-ETS fusion, a
transcription factor, up-regulated Lyn gene expression
[104]. In a survey of primary glioblastomas, Lyn was
found to be the predominant active SFK, compared tonormal brain, or indeed other types of brain tumors
[56], supporting previous work showing Lyn promotes
PDGF-mediated migration of glioblastoma cells [111].
Lyn pathways are also involved in signaling mechanisms
within breast cancer cell lines [105], but it’s expression is
apparently not high or wide-spread in breast cancers.
Undertaking more detailed analysis of Lyn expression in
primary breast cancers and cells lines derived from these
tumors has revealed important functions for Lyn in this
type of cancer [55,73]. Stratifying breast cancer lines by
epithelial/mesenchymal morphology identified Lyn as as-
sociating with a mesenchymal or rather a “basal” type
breast cancer morphology, which also correlated with
reduced overall survival [73]. Basal breast cancers are
known to be more aggressive than their luminalA/B,
normal-like and HER2 counterparts [112]. Knocking
down Lyn in basal type breast cancer cell lines inhibited
their migration and invasion, but not proliferation,
in vitro. In addition, using Dasatinib at concentrations
known to inhibit Lyn, also repressed the invasive capacity
of these cells, but didn’t’ affect their proliferation. A simi-
lar association of Lyn with basal breast cancer was also
uncovered though phospho-tyrosine proteomic profiling
of breast cancers [55]. Again, in the basal type cells ele-
vated phosphorylation of Lyn, as well as Met, EphA2,
EGFR, FAK and p130Cas were noted. Inhibiting or down-
regulating these different active kinases in these cells all
showed significant effects on their biology, including pro-
liferation, migration and invasion. Combining inhibitors of
these different kinases had a greater effect, in particular a
receptor kinase, i.e. EGFR, and a cytoplasmic kinase, i.e.
Lyn. SFK signaling networks, in particular Lyn, appeared
to be central to the basal cell phenotype, intersecting nu-
merous pathways involving the other activated tyrosine
kinases in these cells [41]. Interestingly, Lyn is also present
in luminal progenitors, thought to be the cells-of-origin
for basal breast cancer, supporting speculation that abnor-
mal Lyn signaling helps drive the basal cancer cell
phenotype.
Thus several lines of evidence point to a significant in-
volvement of Lyn in solid tumor development, as well as
leukaemias. Further, solely deleting or hyper-activating
Lyn on its own has little direct influence upon the
prevalence of leukaemia or cancer [20,34], but as this
enzyme is important for particular neoplasms (reviewed
above), it must therefor be concluded that a dysregula-
tion of pathways/substrates/regulators/adaptors, inter-
sected by Lyn, rather than just Lyn itself, is what
potentiates these particular cancers and leukaemias.
Conclusions
Numerous cell lineages of the hematopoietic system
(with the notable exception of T-cells), as well as pro-
genitor cells, utilize Lyn in complex signaling pathways,
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initiated networks. It’s critical role in B-cell receptor sig-
naling has highlighted its modulating capacity via acti-
vating as well as inhibiting down-stream pathways.
Phosphorylation and protein-protein interactions regu-
late Lyn activity, and new data suggests the two isoforms
of Lyn, which differ in the presence/absence of a pY
motif (pY32), may have different biological functions,
potentially explaining its duality in activating and inhi-
biting signaling. Lyn’s regulation of immune cell function
suggests it may be important for immune diseases; in-
deed dysregulation of Lyn can lead to autoimmune dis-
eases in mice, reminiscent of SLE, asthma and psoriasis.
While Lyn rarely appears as an initiator of leukaemogen-
esis, mounting evidence implicates it in playing a role in
maintaining the leukemic phenotype in a variety of li-
quid cancers, including AML, CML, B-ALL and B-CLL.
In addition to being a hematopoietic kinase, Lyn is also
expressed in other tissues, and has a recognized onco-
genic role in solid cancers of these organs, including
prostate, basal breast, and colon cancer, as well as
Ewing’s sarcoma and glioblastoma. With several anti-
cancer drugs being potent Lyn inhibitors, it is going to
be important to address the role that Lyn and its path-
ways play in these different neoplasms.
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